When Beond Ibogaine announced its U.S. headquarters in Austin this past April, the timing seemed almost too perfect. In December, Texas had awarded $50 million to UTHealth Houston and UTMB Health to lead statewide ibogaine clinical trials—the largest public bet on the controversial psychedelic in American history. The White House was signaling openness to fast-tracking treatments. And here was a Cancún-based clinic, already claiming thousands of patients treated, planting its flag in the heart of it all.
But try to figure out how much money Beond has actually raised, and you'll find yourself down a rabbit hole that says as much about the psychedelic therapy industry's opacity as it does about the internet's capacity for confusion.
The problem? There's another company called Beond—a Maldives-based boutique airline that closed a $13 million funding round in December 2023. That figure, splashed across aviation trade publications and wire services, has migrated into aggregator databases and AI-generated company profiles, where it now masquerades as capital raised by the ibogaine clinic. The two companies share nothing but a name. One flies tourists to tropical islands; the other administers a powerful, sometimes dangerous alkaloid derived from African shrubs to treat addiction and PTSD.
The mix-up has created a hall of mirrors for anyone trying to assess Beond Ibogaine's actual financial footing. And that matters, because the psychedelic therapy sector—awash in hope, hype, and regulatory uncertainty—desperately needs clearer disclosure norms as institutional money begins to flow in earnest.
Following the Money, or Trying To
Dealroom, a European venture database, shows that Beond raised an undisclosed seed round in October 2021 from Focalpoint Ventures. StartupSeeker, which explicitly warns that its AI-generated data "may contain errors," lists total funding at "$20M+" or "$25 million" as of December 2025, though these figures remain unverified. No press releases confirm those numbers. Neither do SEC filings. CB Insights labels the company "Seed | Alive" but offers no dollar figures.
In other words, nobody outside Beond's boardroom—and perhaps not everyone inside it—seems to know for sure.
CEO Tom Feegel told the Associated Press in mid-April that the clinic treated roughly 2,000 people in 2025, charging between $15,000 and $20,000 per person for multi-day programs. About 100 veterans received free treatment, he said. The company's website claims "over 3,000" patients treated historically, though that figure comes from marketing copy, not an independent audit.
If you do the back-of-the-envelope math—2,000 patients at an average of $17,500 each—you land somewhere around $35 million in annual revenue. That would be a strong performance for a private clinic operating in a legal gray zone. But without audited financials or verified patient counts, investors are left making educated guesses.
Texas Goes All In
Beond's Austin expansion arrived at a moment when ibogaine, long relegated to the fringes of psychedelic research, was suddenly being taken seriously by state governments and federal regulators. In December, Texas awarded $50 million to UTHealth Houston and UTMB Health to lead statewide clinical trials examining ibogaine's potential for treating traumatic brain injury and PTSD—particularly among veterans. The funding dwarfed previous public commitments.
Then came the policy signal from Washington. On April 18, President Trump signed an executive order directing federal agencies to accelerate review pathways for psychedelics, including ibogaine. The FDA followed up on April 24 with a statement pledging faster approvals for treatments addressing "serious mental illness." Whether that rhetoric translates into regulatory action remains to be seen, but the sector noticed.
Beond's Cancún facility, which opened in February 2022, operates as a licensed medical center under Mexican law, where ibogaine has been legal for decades. The Austin office won't administer the compound itself—ibogaine remains a Schedule I controlled substance in the U.S., lumped in with heroin and LSD. Instead, the Texas location will handle education, patient screening, and post-treatment integration. The clinical work stays south of the border.
It's a model that other psychedelic therapy providers have explored: operate where the drugs are legal, but market and coordinate from jurisdictions with deeper pockets and better infrastructure. It also creates regulatory arbitrage that makes oversight... complicated.
An Industry Built on Smoke Signals
Beond's funding opacity isn't an outlier—it's closer to the norm. The psychedelic therapy sector, spanning clinics, analog drug developers, and advocacy organizations, operates in a disclosure environment that would make traditional biotech investors uneasy. Many companies are privately held, venture-backed, and domiciled in jurisdictions with lighter reporting requirements. Funding announcements are often vague, delayed, or contradictory depending on which database you consult.
Take DemeRx, which is developing an oral noribogaine compound (a synthetic cousin of ibogaine) for alcohol use disorder. The company announced FDA acceptance of its investigational new drug application in April and disclosed a $1.7 million small business grant in October 2025. But broader capitalization details? Scarce. MindMed, one of the better-known players, completed a Phase 1 trial for its ibogaine analog 18-MC back in January 2022, then quietly deprioritized the program. Supply chain companies like Optimi Health have positioned themselves around the Texas trial infrastructure, but the financial architecture of the ecosystem remains sketchy at best.
Independent pricing data compiled by Ibogaine Treatment Guide shows 2026 clinic costs ranging from $6,500 to over $25,000, with Beond's entry-level "Tier 1" program listed at around $12,500 for a roughly 10-day stay. The wide variance reflects differences in medical oversight, facility amenities, and aftercare services. It also reflects the absence of standardized reporting that would let patients or payers compare options meaningfully.
What's Real and What Isn't
Beond has been busy on the operational side. In February, it appointed Dr. Alejandro Junger—author and integrative medicine practitioner—as its Integrative Medicine Lead. In January, the company launched "Beond Service," a veterans-focused treatment program, though independent verification of participant numbers hasn't appeared in mainstream outlets. The company also runs the Beond Ibogaine Research and Policy Institute, a separate entity focused on advocacy and awareness.
Whether any of this translates into durable competitive advantage is harder to say. Ibogaine carries serious medical risks—cardiac complications are well-documented, and deaths have occurred in clinical and non-clinical settings. The compound's legal status in the U.S. remains a wildcard; Schedule I reclassification would require congressional action or a major FDA breakthrough. And the clinic model itself faces competition from hospital-based research programs that may eventually offer ibogaine under more controlled, insurance-reimbursable conditions.
For now, though, Beond occupies a curious position: visible enough to draw attention, opaque enough to frustrate due diligence. That's a problem not just for investors trying to value the company, but for a sector that badly needs credibility as it scales. Texas's $50 million commitment and shifting federal posture suggest institutional capital is coming. The question is whether transparency norms will arrive in time to meet it.
In the meantime, if you're researching Beond Ibogaine and stumble across that $13 million figure, do yourself a favor: check whether you're reading about a psychedelic clinic or a regional airline. The internet, it turns out, doesn't always know the difference.
